tradingkey.logo

STAAR Surgical Co

STAA
View Detailed Chart

27.160USD

0.000
Close 09/18, 16:00ETQuotes delayed by 15 min
1.34BMarket Cap
LossP/E TTM

STAAR Surgical Co

27.160

0.000
Intraday
1m
30m
1h
D
W
M
D

Today

0.00%

5 Days

-3.28%

1 Month

-2.97%

6 Months

+48.58%

Year to Date

+11.82%

1 Year

-13.48%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated2025-09-17

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite an average stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
117 / 207
Overall Ranking
295 / 4723
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 9 analysts
Hold
Current Rating
24.625
Target Price
-9.57%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. These lenses provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. The Company is a manufacturer of lenses used worldwide in corrective or refractive surgery. It sells its products in approximately 75 countries, with direct distribution in Japan, Germany, Spain, the United States, Canada, the United Kingdom, and Singapore, with a combination of direct distribution and independent distribution in China, Korea, India, France, Benelux, and Italy. The Company markets and sells ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. The Company’s EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The Company also markets and sells an ICL lens to treat hyperopia (farsightedness), which is called Visian ICL.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD 20.21M.%!(EXTRA int=2)
Undervalued
The company’s latest PE is -14.07, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 53.99M shares, decreasing 9.46% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 4.38M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 2.61.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. These lenses provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. The Company is a manufacturer of lenses used worldwide in corrective or refractive surgery. It sells its products in approximately 75 countries, with direct distribution in Japan, Germany, Spain, the United States, Canada, the United Kingdom, and Singapore, with a combination of direct distribution and independent distribution in China, Korea, India, France, Benelux, and Italy. The Company markets and sells ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. The Company’s EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The Company also markets and sells an ICL lens to treat hyperopia (farsightedness), which is called Visian ICL.
Ticker SymbolSTAA
CompanySTAAR Surgical Co
CEOMr. Stephen C. (Steve) Farrell, CPA
Websitehttps://www.staar.com/
KeyAI